Recent Finacing
Recent Raise
Odimma Therapeutics develops ODI-2001, a personalized cancer immunotherapy, conducts preclinical proof-of-activity, secured production processes and partnerships for neoepitope AI, synthetic DNA and viral components, and preparing a Phase I trial.
